Affordable Access

Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia.

Authors
Type
Published Article
Journal
Anticancer Research
0250-7005
Publisher
International Institute of Anticancer Research
Publication Date
Volume
19
Issue
4C
Pages
3399–3402
Identifiers
PMID: 10629626
Source
Medline

Abstract

Immunocytochemistry was used to analyze the expression of the Fas ligand (FasL) in sixty-four children with newly diagnosed acute lymphoblastic leukemia (ALL). FasL expression was detected in 55 of 64 children (86%). Children with newly diagnosed ALL and FasL expression exhibited longer relapse-free and overall survival times under chemotherapy than did patients who did not express the Fas ligand. These data suggest that Fas/FasL mediated signaling may play a general role in the cytotoxicity of anticancer drugs.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F